Tarik Asselah
Overview
Explore the profile of Tarik Asselah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
233
Citations
6090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramier C, Protopopescu C, Di Beo V, Parlati L, Marcellin F, Carrat F, et al.
Liver Int
. 2025 Mar;
45(4):e70065.
PMID: 40087922
Background And Aims: Early assessment of hepatocellular carcinoma (HCC) risk could improve long-term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not...
2.
Vaittinada Ayar P, Abdelkader J, Gay M, Allali R, De Freitas C, Monnier B, et al.
J Viral Hepat
. 2025 Mar;
32(4):e70018.
PMID: 40052680
People with mental health disorders have a significant lack of physical health care. They also have higher rates of medical co-morbidity. The aim of this study was to assess the...
3.
Nahon P, Lusivika-Nzinga C, Merle P, Zoulim F, Decaens T, Ganne-Carrie N, et al.
J Hepatol
. 2025 Feb;
PMID: 40020929
Background And Aims: The objective was to describe the dynamics of noninvasive tests (NITs) in cirrhotic patients following sustained virological response (SVR) and to assess their correlation with hepatocellular carcinoma...
4.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
5.
Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado L, et al.
N Engl J Med
. 2025 Jan;
391(22):2098-2109.
PMID: 39774313
Background: Xalnesiran, a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome and silences multiple HBV transcripts, may have efficacy, with or without...
6.
Asselah T, Lampertico P, Aleman S, Bourliere M, Streinu-Cercel A, Bogomolov P, et al.
Liver Int
. 2024 Dec;
45(4):e16174.
PMID: 39648559
Background And Aims: The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients...
7.
Nicolas C, Domas Q, Pol S, Bardou-Jacquet E, Loustaud-Ratti V, Metivier S, et al.
Liver Int
. 2024 Nov;
45(4):e16158.
PMID: 39530494
Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%. Methods And Results: Here we...
8.
Cornberg M, Huppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Marino Z, et al.
Adv Ther
. 2024 Oct;
41(12):4669-4682.
PMID: 39470876
Introduction: This brief report presents updated findings from the previously published CREST study evaluating the safety and effectiveness of 8-week glecaprevir/pibrentasvir (GLE/PIB) in treatment-naïve patients with chronic hepatitis C virus...
9.
Roulot D, Layese R, Brichler S, Ganne N, Asselah T, Zoulim F, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39461464
Background & Aims: The specific causative role of hepatitis delta virus (HDV) infection in the development of hepatocellular carcinoma (HCC) remains debated and was not specifically demonstrated in patients with...
10.
De Broucker C, Asselah T
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39426644
No abstract available.